{"url_path":"/sec/trvi/8-k/2026-06-04/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-257365-index.html","accession_number":"0001193125-26-257365","cik":"0001563880","ticker":"TRVI","issuer_name":"Trevi Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-257365-index.html","primary_entity_key":"0001563880","primary_entity_name":"Trevi Therapeutics, Inc."},"word_count":123,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits\n\n(d) Exhibits\n\nExhibit No.\n\nDescription\n\n \n\n \n\n \n\n3.1\n\n \n\n[Certificate of Amendment to the Restated Certificate of Incorporation, as amended, of Trevi Therapeutics, Inc.](trvi-ex3_1.htm)\n\n99.1\n\n[Amended and Restated 2019 Stock Incentive Plan (incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 21, 2026).](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001563880/000119312526166695/trvi-20260421.htm#appendix_a)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nTREVI THERAPEUTICS, INC.\n\n \n\n \n\n \n\nDate: June 4, 2026\n\n \n\nBy:\n\n/s/ David C. Hastings\n\n \n\n \n\n \n\nName: David C. Hastings\n\n \n\n \n\n \n\nTitle: Chief Financial Officer"}